References

1. Adham N, Bard JA, Zgombick JM, Durkin MM, Kucharewicz S, Weinshank RL, Branchek TA. (1997) Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology, 36 (4-5): 569-76. [PMID:9225282]

2. Adham N, Gerald C, Schechter L, Vaysse P, Weinshank R, Branchek T. (1996) [3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor. Eur J Pharmacol, 304 (1-3): 231-5. [PMID:8813606]

3. Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA. (1993) Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA, 90 (2): 408-12. [PMID:8380639]

4. Almaula N, Ebersole BJ, Zhang D, Weinstein H, Sealfon SC. (1996) Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem, 271 (25): 14672-5. [PMID:8663249]

5. Bach T, Syversveen T, Kvingedal AM, Krobert KA, Brattelid T, Kaumann AJ, Levy FO. (2001) 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmacol, 363 (2): 146-60. [PMID:11218067]

6. Bai F, Yin T, Johnstone EM, Su C, Varga G, Little SP, Nelson DL. (2004) Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol, 484 (2-3): 127-39. [PMID:14744596]

7. Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL. (1993) Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem, 268 (31): 23422-6. [PMID:8226867]

8. Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N et al.. (2004) The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol, 143 (5): 549-60. [PMID:15466450]

9. Belelli D, Balcarek JM, Hope AG, Peters JA, Lambert JJ, Blackburn TP. (1995) Cloning and functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. Mol Pharmacol, 48 (6): 1054-62. [PMID:8848005]

10. Bender E, Pindon A, van Oers I, Zhang YB, Gommeren W, Verhasselt P, Jurzak M, Leysen J, Luyten W. (2000) Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant. J Neurochem, 74 (2): 478-89. [PMID:10646498]

11. Blondel O, Gastineau M, Dahmoune Y, Langlois M, Fischmeister R. (1998) Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J Neurochem, 70 (6): 2252-61. [PMID:9603189]

12. Boess FG, Monsma FJ, Meyer V, Zwingelstein C, Sleight AJ. (1997) Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor. Mol Pharmacol, 52: 515-523. [PMID:9284367]

13. Boess FG, Monsma Jr FJ, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ. (1997) Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology, 36 (4-5): 713-20. [PMID:9225298]

14. Boess FG, Monsma Jr FJ, Sleight AJ. (1998) Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem, 71 (5): 2169-77. [PMID:9798944]

15. Boess FG, Riemer C, Bos M, Bentley J, Bourson A, Sleight AJ. (1998) The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol, 54: 577-583. [PMID:9730917]

16. Bonhaus DW, Berger J, Adham N, Branchek TA, Hsu SA, Loury DN, Leung E, Wong EH, Clark RD, Eglen RM. (1997) [3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology, 36 (4-5): 671-9. [PMID:9225293]

17. Brady CA, Stanford IM, Ali I, Lin L, Williams JM, Dubin AE, Hope AG, Barnes NM. (2001) Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology, 41 (2): 282-4. [PMID:11489465]

18. Branchek T, Adham N, Macchi M, Kao HT, Hartig PR. (1990) [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mol Pharmacol, 38 (5): 604-9. [PMID:2233697]

19. Claeysen S, Faye P, Sebben M, Lemaire S, Bockaert J, Dumuis A. (1997) Cloning and expression of human 5-HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase. Neuroreport, 8 (15): 3189-96. [PMID:9351641]

20. Claeysen S, Sebben M, Journot L, Bockaert J, Dumuis A. (1996) Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor. FEBS Lett, 398 (1): 19-25. [PMID:8946946]

21. Dang H, England PM, Farivar SS, Dougherty DA, Lester HA. (2000) Probing the role of a conserved M1 proline residue in 5-hydroxytryptamine(3) receptor gating. Mol Pharmacol, 57 (6): 1114-22. [PMID:10825381]

22. Davidson C, Ho M, Price GW, Jones BJ, Stamford JA. (1997) (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors. Br J Pharmacol, 121 (4): 737-42. [PMID:9208142]

23. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF. (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature, 397 (6717): 359-63. [PMID:9950429]

24. Dubin AE, Huvar R, D'Andrea MR, Pyati J, Zhu JY, Joy KC, Wilson SJ, Galindo JE, Glass CA, Luo L et al.. (1999) The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit. J Biol Chem, 274 (43): 30799-810. [PMID:10521471]

25. Dukat M, Smith C, Herrick-Davis K, Teitler M, Glennon RA. (2004) Binding of tryptamine analogs at h5-HT1E receptors: a structure-affinity investigation. Bioorg Med Chem, 12 (10): 2545-52. [PMID:15110837]

26. Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K. (2000) Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse, 35: 144-150. [PMID:10611640]

27. Egan CT, Herrick-Davis K, Teitler M. (1998) Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther, 286 (1): 85-90. [PMID:9655845]

28. Engel K, Wang J. (2005) Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol, 68 (5): 1397-407. [PMID:16099839]

29. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA, 93 (10): 5166-71. [PMID:8643547]

30. Erlander MG, Lovenberg TW, Baron BM, de Lecea L, Danielson PE, Racke M, Slone AL, Siegel BW, Foye PE, Cannon K et al.. (1993) Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. Proc Natl Acad Sci USA, 90 (8): 3452-6. [PMID:7682702]

31. Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR. (1999) High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem, 72 (5): 2127-34. [PMID:10217294]

32. Gerald C, Adham N, Kao HT, Olsen MA, Laz TM, Schechter LE, Bard JA, Vaysse PJ, Hartig PR, Branchek TA et al.. (1995) The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J, 14 (12): 2806-15. [PMID:7796807]

33. Grailhe R, Grabtree GW, Hen R. (2001) Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol, 418 (3): 157-67. [PMID:11343685]

34. Hamblin MW, Metcalf MA. (1991) Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol, 40 (2): 143-8. [PMID:1652050]

35. Hameg A, Bayle F, Nuss P, Dupuis P, Garay RP, Dib M. (2003) Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol, 65 (3): 435-40. [PMID:12527336]

36. Herrick-Davis K, Egan C, Teitler M. (1997) Activating mutations of the serotonin 5-HT2C receptor. J Neurochem, 69 (3): 1138-44. [PMID:9282936]

37. Hope AG, Peters JA, Brown AM, Lambert JJ, Blackburn TP. (1996) Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells. Br J Pharmacol, 118 (5): 1237-45. [PMID:8818349]

38. Ito H, Kiso T, Miyata K, Kamato T, Yuki H, Akuzawa S, Nagakura Y, Yamano M, Suzuki M, Naitoh Y et al.. (2000) Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro. Eur J Pharmacol, 409 (2): 195-201. [PMID:11104834]

39. Jasper JR, Kosaka A, To ZP, Chang DJ, Eglen RM. (1997) Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol, 122 (1): 126-32. [PMID:9298538]

40. Johnson MP, Loncharich RJ, Baez M, Nelson DL. (1994) Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol, 45 (2): 277-86. [PMID:8114677]

41. Kalipatnapu S, Pucadyil TJ, Harikumar KG, Chattopadhyay A. (2004) Ligand binding characteristics of the human serotonin1A receptor heterologously expressed in CHO cells. Biosci Rep, 24 (2): 101-15. [PMID:15628665]

42. Kimura Y, Hatanaka K, Naitou Y, Maeno K, Shimada I, Koakutsu A, Wanibuchi F, Yamaguchi T. (2004) Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. Eur J Pharmacol, 483 (1): 37-43. [PMID:14709324]

43. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M. (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol, 370 (2): 114-23. [PMID:15322733]

44. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW. (1996) Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem, 66 (1): 47-56. [PMID:8522988]

45. Krobert KA, Bach T, Syversveen T, Kvingedal AM, Levy FO. (2001) The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch Pharmacol, 363 (6): 620-32. [PMID:11414657]

46. Kursar JD, Nelson DL, Wainscott DB, Baez M. (1994) Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol, 46 (2): 227-34. [PMID:8078486]

47. Lankiewicz S, Lobitz N, Wetzel CH, Rupprecht R, Gisselmann G, Hatt H. (1998) Molecular cloning, functional expression, and pharmacological characterization of 5-hydroxytryptamine3 receptor cDNA and its splice variants from guinea pig. Mol Pharmacol, 53 (2): 202-12. [PMID:9463477]

48. Leysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, Haegeman G, Schotte A, Van Gompel P, Wouters R et al.. (1996) Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol, 50 (6): 1567-80. [PMID:8967979]

49. Lovenberg TW, Erlander MG, Baron BM, Racke M, Slone AL, Siegel BW, Craft CM, Burns JE, Danielson PE, Sutcliffe JG. (1993) Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci USA, 90 (6): 2184-8. [PMID:8384716]

50. Maroteaux L, Saudou F, Amlaiky N, Boschert U, Plassat JL, Hen R. (1992) Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci USA, 89 (7): 3020-4. [PMID:1557407]

51. Matthes H, Boschert U, Amlaiky N, Grailhe R, Plassat JL, Muscatelli F, Mattei MG, Hen R. (1993) Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol, 43 (3): 313-9. [PMID:8450829]

52. May JA, Chen HH, Rusinko A, Lynch VM, Sharif NA, McLaughlin MA. (2003) A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem, 46 (19): 4188-95. [PMID:12954071]

53. McAllister G, Charlesworth A, Snodin C, Beer MS, Noble AJ, Middlemiss DN, Iversen LL, Whiting P. (1992) Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci USA, 89 (12): 5517-21. [PMID:1608964]

54. Metzner L, Kottra G, Neubert K, Daniel H, Brandsch M. (2005) Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J, 19 (11): 1468-73. [PMID:16126914]

55. Mialet J, Berque-Bestel I, Eftekhari P, Gastineau M, Giner M, Dahmoune Y, Donzeau-Gouge P, Hoebeke J, Langlois M, Sicsic S et al.. (2000) Isolation of the serotoninergic 5-HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6-glial and CHO cell lines. Br J Pharmacol, 129 (4): 771-81. [PMID:10683202]

56. Mialet J, Berque-Bestel I, Sicsic S, Langlois M, Fischmeister R, Lezoualc'h F. (2000) Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells. Br J Pharmacol, 131 (4): 827-35. [PMID:11030734]

57. Mialet J, Dahmoune Y, Lezoualc'h F, Berque-Bestel I, Eftekhari P, Hoebeke J, Sicsic S, Langlois M, Fischmeister R. (2000) Exploration of the ligand binding site of the human 5-HT(4) receptor by site-directed mutagenesis and molecular modeling. Br J Pharmacol, 130 (3): 527-38. [PMID:10821780]

58. Miyake A, Mochizuki S, Takemoto Y, Akuzawa S. (1995) Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol, 48 (3): 407-16. [PMID:7565620]

59. Monsma Jr FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol, 43 (3): 320-7. [PMID:7680751]

60. Newman-Tancredi A, Audinot V, Moreira C, Verrièle L, Millan MJ. (2000) Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. Mol Pharmacol, 58 (5): 1042-9. [PMID:11040052]

61. Newman-Tancredi A, Conte C, Chaput C, Verrièle L, Audinot-Bouchez V, Lochon S, Lavielle G, Millan MJ. (1997) Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol, 355 (6): 682-8. [PMID:9205951]

62. Newman-Tancredi A, Cussac D, Audinot V, Millan MJ. (1999) Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol, 359 (6): 447-53. [PMID:10431754]

63. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, Millan MJ. (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol, 355 (2-3): 245-56. [PMID:9760039]

64. Newman-Tancredi A, Verrièle L, Chaput C, Millan MJ. (1998) Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. Naunyn Schmiedebergs Arch Pharmacol, 357 (3): 205-17. [PMID:9550290]

65. Newman-Tancredi A, Wootton R, Strange PG. (1992) High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells. Biochem J, 285 ( Pt 3): 933-8. [PMID:1386736]

66. Parker EM, Izzarelli DG, Lewis-Higgins L, Palmer D, Shapiro RA. (1996) Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem, 67 (5): 2096-103. [PMID:8863519]

67. Plassat JL, Amlaiky N, Hen R. (1993) Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol, 44 (2): 229-36. [PMID:8394987]

68. Rees S, den Daas I, Foord S, Goodson S, Bull D, Kilpatrick G, Lee M. (1994) Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett, 355 (3): 242-6. [PMID:7988681]

69. Rivail L, Giner M, Gastineau M, Berthouze M, Soulier JL, Fischmeister R, Lezoualc'h F, Maigret B, Sicsic S, Berque-Bestel I. (2004) New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket. Br J Pharmacol, 143 (3): 361-70. [PMID:15351779]

70. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 102 (23): 2836-41. [PMID:11104741]

71. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC. (1993) Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci USA, 90 (18): 8547-51. [PMID:8397408]

72. Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Collin L, Jones BJ, Middlemiss DN, Price GW. (1998) SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol, 125 (1): 202-8. [PMID:9776361]

73. Shapiro DA, Kristiansen K, Kroeze WK, Roth BL. (2000) Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol, 58 (5): 877-86. [PMID:11040033]

74. Shen Y, Monsma Jr FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. (1993) Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem, 268 (24): 18200-4. [PMID:8394362]

75. Sleight AJ, Stam NJ, Mutel V, Vanderheyden PM. (1996) Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities. Biochem Pharmacol, 51 (1): 71-6. [PMID:8534270]

76. Solt K, Stevens RJ, Davies PA, Raines DE. (2005) General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition. J Pharmacol Exp Ther, 315 (2): 771-6. [PMID:16081679]

77. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB. (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature, 350 (6319): 614-9. [PMID:1826762]

78. Thomas DR, Gittins SA, Collin LL, Middlemiss DN, Riley G, Hagan J, Gloger I, Ellis CE, Forbes IT, Brown AM. (1998) Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. Br J Pharmacol, 124 (6): 1300-6. [PMID:9720804]

79. Van den Wyngaert I, Gommeren W, Verhasselt P, Jurzak M, Leysen J, Luyten W, Bender E. (1997) Cloning and expression of a human serotonin 5-HT4 receptor cDNA. J Neurochem, 69 (5): 1810-9. [PMID:9349523]

80. Wainscott DB, Cohen ML, Schenck KW, Audia JE, Nissen JS, Baez M, Kursar JD, Lucaites VL, Nelson DL. (1993) Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol, 43 (3): 419-26. [PMID:8450835]

81. Wainscott DB, Krushinski Jr JH, Audia JE, Schaus JM, Zgombick JM, Lucaites VL, Nelson DL. (2005) [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedebergs Arch Pharmacol, 371 (3): 169-77. [PMID:15900510]

82. Wang J. (2016) The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition. Clin Pharmacol Ther, 100 (5): 489-499. [PMID:27506881]

83. Watson JM, Burton MJ, Price GW, Jones BJ, Middlemiss DN. (1996) GR127935 acts as a partial agonist at recombinant human 5-HT1D alpha and 5-HT1D beta receptors. Eur J Pharmacol, 314 (3): 365-72. [PMID:8957260]

84. Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR. (1992) Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci USA, 89 (8): 3630-4. [PMID:1565658]

85. Weiss HM, Haase W, Michel H, Reiländer H. (1995) Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett, 377 (3): 451-6. [PMID:8549774]

86. Zhu HJ, Appel DI, Gründemann D, Markowitz JS. (2010) Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem, 114 (1): 142-9. [PMID:20402963]